Are you G Morlock?

Claim your profile

Publications (19)7.48 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: To assess the optimal dosage of oral tiludronate in Paget's disease of bone. We studied 149 patients with Paget's disease, in a double-blind, randomized, placebo-controlled trial. Patients were randomly assigned to 1 of 5 therapeutic groups: a daily dose of 100 mg, 200 mg, 400 mg, or 800 mg of oral tiludronate, or a placebo. Treatment was for 3 months, followed by 3 months of placebo-controlled followup. Serum alkaline phosphatase activity (SAP) and fasting urinary excretion of hydroxyproline/creatinine (OH/Cr) were measured monthly, as were biochemical parameters reflecting renal, hepatic, and hematologic functions. Analgesic efficacy was self-evaluated from a visual analog scale and a global pain index. Statistical analysis revealed that beginning at a dosage of 200 mg/day, there was a direct dose-dependent effect on the reduction of SAP and OH/Cr levels. Reduction of SAP levels was clinically significant at a dosage of 400 mg (44.9 +/- 4.2% reduction at 90 days and 49.2 +/- 4.5% at 180 days, mean +/- SEM) and at 800 mg (53.4 +/- 5% at 90 days and 59.3 +/- 4.6% at 180 days). There was a significant reduction in pain in all groups, including the group taking placebo. In only those taking 800 mg/day of tiludronate was there a significant frequency of complete resolution of pain (versus placebo). Aside from mild gastrointestinal disturbances, as experienced with other oral bisphosphonates, clinical tolerance of all 5 regimens was good. Exhaustive biochemical investigations failed to reveal significant toxicity of tiludronate up to the 800-mg daily dose investigated. Because of its significantly better antiresorptive effects and greater analgesic properties (compared with lower dosages), combined with the excellent clinical and biochemical tolerance, the 800-mg daily dose of tiludronate appears to be optimal for the treatment of Paget's disease of bone.
    Arthritis & Rheumatology 09/1992; 35(8):967-74. · 7.48 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The tumor mass regression following the first course of treatment (T1), the time to greater than or equal to 50% tumor regression (TR 50%) and the time to maximum regression (t) were assessed in 29 out of 55 multiple myelomas (MM) successfully treated with alkylating agents. According to t, TR 50% and T1 values, 3 distinctive categories of responsive patients were separated: 1) fast responsive patients (= t less than or equal to 2 months, 48% of cases); 2) intermediate responsive patients (= 3 less than t or 12 months, 38%); 3) and slow responsive patients (= t greater than 12 months, 14%). The first remission duration was shown to be highly related to t (p less than .001), TR 50% (p less than .01) and T1 (p less than .05), the shortest remissions being observed in fast responsive patients. In relapse, the tumor doubling time (TD) was correlated with t, TR 50% and T1 (p = .05), the shortest TD being observed in fast responsive patients. It was shown that pure Bence-Jones and hypercalcemic myelomas were the fastest responsive patients.
    Revue du rhumatisme et des maladies ostéo-articulaires 06/1981; 48(5):413-8.
  • [Show abstract] [Hide abstract]
    ABSTRACT: In order to study the response of patients with multiple myeloma of the bones (MM) to various anti-cancer drugs (Melphalan M, Cyclophosphamide Cy, Nitrosourea NU, Vincristine V, Adriamycine A and Prednisone P), 70 MM received the following treatment : 1) Induction therapy : a) M and P or b) M and Cy and P ; 2) Levelling with partial or complete response : V Cy P (in case a) or V M Cy P (in case b) ; 3) Relapse : A and NU. The following results were obtained : 1) Only 42.6% of patients respond to induction therapy ; 2) Fewer than 10% of patients showing a response reach a second levelling with Vincristine ; 3) 50% of those not showing a response reach a levelling between --20 and --50 and have prolonged survival ; 4) Only 20% of non responders are improved by Cy P or A and NU. The median actuarial survival is 42 months. Among the responders two poor prognosis factors must be underlined : hypercalcemia and the speed of response.
    Revue du rhumatisme et des maladies ostéo-articulaires 03/1980; 47(2):77-82.
  • [Show abstract] [Hide abstract]
    ABSTRACT: The authors have made a retrospective study of 243 cases of multiple myelomas, most of them treated with alkylating agents. The average age at the time of diagnosis was 65 years (+ 10). The ratio of the sexes was 1 : 1. Seventy two per cent of the patients had a bone rating of 2 or 3 according to the criteria of Durie and Salmon. Fifty-eight per cent of the patients were anemic (Hg 12 g per cent), with less than 15 per cent being leucopenic or thrombopenic. Hypercalcemia (105 mg 0/00) was noted in 27 per cent of cases. The distribution of immunochemical types is as follows : IgG, 51.5 per cent; IgA, 28 per cent; pure Bence Jones, 20.5 per cent. The respective percentages of kappa and lambda light chains were 64.2 per cent and 35.8 per cent. In this series, nearly 80 per cent of the patients were at phase III according to the classification of Durie and Salmon, and 30.8 per cent at phase B. The median survival, including all phases, increased from 8 months without alkylating agent, to 20 months with melphalan and/or cyclophosphamide. The factors influencing the survival of the patients treated were age, the hemoglobin level, calcemia, renal deficiencies, the immunochemical type, the stage of the disease, and the response to alkylating treatment. The value of these different prognostic factors is discussed.
    Revue du rhumatisme et des maladies ostéo-articulaires 03/1979; 46(2):77-83.
  • [Show abstract] [Hide abstract]
    ABSTRACT: In reference to 22 recent cases of multiple myeloma the authors underline the value of estimating the tumour size and its variations under treatment, according to the method of Salmon and Durie. This allows an estimation of the initial prognosis and rapide evaluation of the response to treatment given, permitting a truly strategic approach to the treatment of multiple myeloma.
    Revue du rhumatisme et des maladies ostéo-articulaires 02/1978; 45(1):1-5.
  • Revue du rhumatisme et des maladies ostéo-articulaires 11/1977; 44(10):541-6.
  • J Sany, G Morlock, J Clot, H Serre
    [Show abstract] [Hide abstract]
    ABSTRACT: Twenty selected patients suffering from severe, long-standing rhumatoid arthritis (RA) not controlled by anti-inflammatory drugs (19 cases) and from disseminated lupus erythematosis (DLE) (1 case) were treated with levamisole. The subjects were divided into 2 groups: Group I comprised fourteen patients (13 RA and 1 DLE) treated continuously by levamisole 150 mg/day for 3 or 6 months then on an intermittent regime (150 mg/day-3 days per week). Group II comprised 6 RA patients treated on the intermittent regime from the beginning. In Group I, following average treatment of 9 months (5-12 months), clinical results assessed according to precise clinical criteria were favorable in 9 out of eleven cases. In the other 2 cases no change was noted. Side effects included reversible agranulocytosis in 9 cases, on 3 occasions this necessitated the discontinuation of treatment. A signifcant reduction in sedimentation rate was noticed in 5 cases out of eleven and in 3 patients the Rose-Waller test turned negative. A monoclonal disglobulinemia of IgG lambda appeared under treatment in 1 patient who was deficient in IgA. Skin tests carried out periodically showed a significant augmentation of the response to candida. Lymphocyte culture in the presence of mitogens gave highly variable results from one control to the other in the same subject, as well as in the treated subjects as in the group of RA not receiving levamisole. These results are compared with those previously published; the mechanism of action and possible indications for levamisole in RA are discussed.
    Revue du rhumatisme et des maladies ostéo-articulaires 04/1977; 44(3):143-53.
  • Revue du rhumatisme et des maladies ostéo-articulaires 12/1976; 43(11):669-77.
  • G Morlock, J Sany, H Serre
    La Nouvelle presse médicale 05/1976; 5(17):1145.
  • [Show abstract] [Hide abstract]
    ABSTRACT: The authors report a case of multiple kappa myeloma comboned with chronic lymphoid leukemia. The chronic lymphoid leukemia had evolved over a 13-year period in the classical manner, without serum or urnary monoclonal immunoglobulins. The multiple myeloma with blood and urinary kappa chains appeared suddenly with a typical clinical and radiological picture accompanied by renal insufficiency. Thd diagnosis was confirmed by the demonstration of both lymphocyte and plasmocyte cell proliferation and a study of the ultrastructure which showed the sarcomatous and secretory character of the plasmocytes. A study of plasmocyte subpopulation showed the proliferation of B lymphocytes. A combination of chronic lymphoid leukemia and multiple myeloma is exceptional. The physiopathological interpretation (mono or biclonal proliferation) is discussed in the light of current nosological conceptions concerning lymphoproliferative disorders.
    Revue du rhumatisme et des maladies ostéo-articulaires 02/1976; 43(1):1-9.
  • G Morlock, J Sanvy, H Serre
    [Show abstract] [Hide abstract]
    ABSTRACT: The authors report 12 cases of Paget's disease with sarcomatous degeneration that were observed among 311 patients with Paget's disease hospitalized in the Montpellier Rheumatology Clinic. They compare their experience with information they were able to extract from the literature in French and English. The frequency of such degeneration in cases of Paget's disease is difficult to determine but did not appear to exceed 1%. Degeneration rarely occurred before the age of 50 years, affected men twice as frequently as women, and occurred particularly in cases of diffuse Paget's disease, mainly in the femur or the humerus; the rachis was rarely affected. Pain was the main symptom, was practically constant, was remarkable because of its permanence and its intensity. Tumefaction was frequently seen. Pathological fractures were seen in almost a third of the patients with sarcomas of the long bones. Radiculo-medullary compression characterized the rare cases with involvement of the vertebral column or the sacrum. Radiography showed rupture of cortical layers with invasion of the soft parts without any periostal reaction. Histological investigation confirmed the diagnosis by demonstrating one of the three types of osteogenic sarcoma: osteosarcomas were the most frequent. Less frequently giant-cell sarcomas or reticulosarcomas were found. The affected patients nearly always died, survival at five years being rare. Treatment, amputation or radiotherapy, was disappointing.
    Revue du rhumatisme et des maladies ostéo-articulaires 12/1975; 42(11):669-79.
  • Revue du rhumatisme et des maladies ostéo-articulaires 12/1974; 41(11):685-92.
  • Revue du rhumatisme et des maladies ostéo-articulaires 05/1974; 41(4):265-70.
  • La Nouvelle presse médicale 07/1973; 2(24):1672.
  • G Morlock, J Sany, J Clot, H Serre
    La Nouvelle presse médicale 07/1973; 2(24):1672.
  • Revue du rhumatisme et des maladies ostéo-articulaires 55(9):689-92.
  • G Morlock, R Bataille, J Sany, H Serre
    La semaine des hôpitaux : organe fondé par l'Association d'enseignement médical des hôpitaux de Paris. 53(14-15):853-6.
  • [Show abstract] [Hide abstract]
    ABSTRACT: The authors reviewed the recent data about prognostic factors, criteria of response and chemotherapy in multiple myeloma of bone. They insist on the new staging of durie and salmon anf on the interest of poly chemotherapy.
    La semaine des hôpitaux : organe fondé par l'Association d'enseignement médical des hôpitaux de Paris. 55(31-32):1377-82.
  • [Show abstract] [Hide abstract]
    ABSTRACT: The authors reviewed the recent data about prognostic factors, criteria of response and chemotherapy in multiple myeloma of bone. They insist on the new staging of durie and salmon and on the interest of polychemotherapy.
    La semaine des hôpitaux : organe fondé par l'Association d'enseignement médical des hôpitaux de Paris. 55(27-30):1267-70.